U.S. Markets closed

Sorrento Therapeutics, Inc. (SRNE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
15.23+4.81 (+46.16%)
At close: 4:00PM EST

14.53 -0.70 (-4.60%)
After hours: 4:22PM EST

Sign in to post a message.
  • D
    Don
    Covi-MSC is only one of 8 potential Covid Emergency Use Authorization candidates...all Blockbusters!
    1. Covi-Stix rapid accurate virus test
    2. Covi-Track rapid accurate antibody test
    3. Covi-push 2020 injection
    4. Covi-Drops 2020 nose drops
    5. Covi-Vax 2020 lipid DNA injection
    6. Abivirtinib ARDS prevention
    7. Covi-MSC Stem Cell ARDS treatment
    8. Covi-Shield antibody cocktail
    Each of these EUA's could be accompanied by Operation Warp Speed grants and multi-billion dollar international sales. Additionally there could multi-billion dollar worldwide marketing partnerships. Dr.Ji says there is interest from Mexico, Brazil and Europe.

    Timing? Some could come in days. Some in weeks. Others in several months.

    In addition to these 8 Covid EUA candidates Sorrento has other potential multi $Billion programs ... here are 2 samples from each of the three portfolio areas...with at least 4 with 2021 revenue potential!

    NON-OPIOID PAIN
    1. SP-102 phase 3 over 90% enrolled, fast track, lumbar/sciatic pain
    2. RTX intractable cancer, knee and arthritic pain

    COVID
    1. rapid, accurate, low cost tests. TRACK, TRACE, STIX
    2. 2020 DROPS, injection and plasmid DNA

    CANCER
    1. Abivirtinib NSCLC phase 3, lymphomas phase 2, prostate IND, lupus
    2. SmartPharm plasmid DNA Plus DAR-T and Mayo Clinic ADNIC drugs.

    Do your dd and have a look at the January 2021 presentation. There are several more potential blockbusters IMO!
    https://investors.sorrentotherapeutics.com/static-files/c7e5a3a2-7849-42e7-b531-2e6a7a7f3e94
  • W
    Wise
    Today's price reaction was little taste of what's to come. Congrats longs today...
  • A
    Ariadinvestor
    $AUPH conversation
    Peter Lynch: "If you like a stock at $14 and it goes to $6, that's good if you understand the company. Take advantage of these declines. Know what you own and know why you own it. If you own good companies, you'll do well. It's always going to be scary, there's going to be always something to worry about, and you just have to forget about all of that." AUPH/SRNE has very bright future. Patience is the key to the ultimate success of a true long. AUPH/SRNE's great science & pipeline will shine. God bless $AUPH / $SRNE investors. Cheers!

    link to Peter lynch: https://www.gurufocus.com/news/1105082/peter-lynch-on-having-a-simple-investment-strategy
    link to Peter lynch: https://www.youtube.com/watch?v=MLIxSL1v79g

    God bless $AUPH / $SRNE investors.

    === Junk below this line ===:
    "
    Interesting line in this quotation: "reasonably assured..."

    "R&D expenses decreased to $4.8 million for the third quarter ended September 30, 2020 compared to $17.8 million for the same period in 2019. The decrease is due to a decrease in activities related to clinical trials and exploratory development work and the capitalization of inventory and internal development costs as management believes that approval by the FDA of voclosporin as a treatment for LN was reasonably assured."

    the Bullish Report on Sorrento Therapeutics, Inc.

    https://chart-analysis.tools/SRNE

    Top Gainers in the U.S. Stock Markets 🇺🇸

    https://stockreport.tips/Top-Market-Gainers

    The market expects Sorrento Therapeutics (SRNE - Free Report) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2020. If you want investment ideas from real knowledgeable traders, check them out at the https://investena.today/recommends/exclusive-stock-trading-masterclass/ platform

    "
    Sorrento is said to seek further funding in support of the COVID Gene MAb program toward EUA approval and large-scale manufacturing pending successful clinical studies. Check the disclaimer on the landing page. Meanwhile, these other companies are said to be rapidly growing in the $6.5 approx trillion global e-commerce market, and the approx $4.3 trillion mobile commerce market. Wow! have you heard this one? Let's find more here: http://psce.pw/PotentialECommerceBoom

    Recently, Sorrento Therapeutics announced that they have inked the acquisition of SmartPharm for COVID-19 and rare diseases with broad potential application in enhancing any antibody-centric therapeutics Check disclaimer on landing pages. On the other hand, these other companies are said to be global, more accessible, open alternative to everyday mainstream financial services such as savings, loans, trading, insurance and more! To know more about all of these possible benefits, you could visit this to possibly generate more wealth and attain more useful info: http://psce.pw/PotentialMainstreamServices

    Sorrento Therapeutics, Inc. is believed to be multifaceted when it comes to its journey in finding the Covid 19 vaccine. Check the disclaimer on the landing page. These other companies could fully satisfy your curiosity through its medical treatment for unmet need. Interested how they make waves in the sector?might this be another great choice to have? Look deeper and be enticed here:http://psce.pw/DemandForPharmaceutical

    Sorrento Therapeutics (NASDAQ: SRNE) has taken a broad approach to developing tests, treatments, and vaccines for COVID-19. In the process, the biotech certainly hasn't broken any biotech speed records and trails the leaders in each of the three categories. --------------------------
    If you’re looking for a watchlist covering the great stock setups every day before the open, I recommend https://tradepicker.today/recommends/dailystockwatchlist/ They send daily set ups and its free. It’s a great way to pick out potential trades for the day.

    Sorrento announces IND filing for COVI-DROPS, an intranasal formulation of a high potency neutralizing antibody against SARS-CoV-2. Check disclaimer on landing page. Meanwhile, these other companies are said to have a global, more accessible, open alternative to everyday mainstream financial services such as savings, loans, trading, insurance and more. Isn't it great? It could really help the investors. Know here;
    http://psce.pw/PromisingFinancialEcosystems

    It is said that Sorrento is working on many different COVID-19 programs, including its antibody cocktail COVI-SHIELD, and Abivertinib, which treats cytokine storms. Check the disclaimer on the landing page. On the other hand, these other companies are said to jointly own and operate a new mobile fintech platform that is said to deliver mobile financial services. This could help you to start! watch here!https://www.youtube.com/watch?v=oi388ywikjE&feature=youtu.be

    According to the reports, Sorrento Therapeutics's antibody program candidate is expected to be developed as a stand-alone therapy against COVID-19. Check disclaimer on landing pages. On the other han
    Peter Lynch on Having a Simple Investment Strategy, release date:Apr 15, 2020
    Peter Lynch on Having a Simple Investment Strategy, release date:Apr 15, 2020
    www.gurufocus.com
    Bullish
  • A
    Ariadinvestor
    "I will buy a bottle of Louis XIII to celebrate when AUPH is bought out at $66+. I will invite all my friends to whom I have recommended AUPH," I emailed my friends on 2017-04-02. "I want more gold bags. Shorts, pls bring it down further. The lower, the better. Falling knife? Should it fall further, I would catch more." I also catch SRNE-Falling-Knife as I caught ARIA-Falling-Knife.

    "When ARIA rises to $48.50, I will buy a bottle of Louis XIII to celebrate and invite all my friends to whom I have recommended ARIA. I will sell half of my gold bags of ARIA shares and watch another half of my gold bags being filled with the precious metal of gold in my retirement," I posted in 2012. Unfortunately, ARIA was buyout at $24/share before my dream came true. 死生有命,富贵在天。人算不如天算!"I will buy a bottle of Louis XIII to celebrate when AUPH is bought out at $66+. I will invite all my friends to whom I have recommended AUPH," I wrote to my friends on April 2, 2017.

    My $48.50/share ARIA dream was interrupted by Takeda's $24/share buyout & my dream came only half true. 死生有命,富贵在天。人算不如天算!I will buy a bottle of Louis XIII to celebrate & invite all my friends to whom I've recommended SRNE/AUPH when $SRNE quadruples H.C. Wainwright's $30 price target or $AUPH is bought out at $66.28+. Even if my SRNE/AUPH dream comes half true, it will be $60 or $33 per share. It will be better if my AUPH dream comes fully true although I will spend $3,700 for the Louis XIII I promise. I always track what I've said. 言必信! 干杯 Louis XIII when I dream comes true!

    I emailed my friends Sunday, April 2, 2017 10:03 AM: { I have just posted: "... Ariad got a $5.2B ($24/share) buyout from Takeda. What AUPH's share price would be should Aurinia also get a $5.2B buyout?" Replying to my own post, I attached some links about AUPH. This was what I talked to Dr. Hu when he called me last Thursday to teach me about biopsy: I know AUPH could drop to ZERO should the phase 3 clinical trial of the LN drug failed given Aurinia has only one drug with only one indication unlike Ariad that had a wonderful drug discovery platform. Nevertheless, I still dream about it. Once in a while, a pipe dream comes partially true.}

    https://www.reservebar.com/products/louis-xiii-cognac?utm_source=GoogleShoppingFeed&utm_medium=search&utm_campaign=LouisXIII&gclid=EAIaIQobChMIsJyuhLS17gIVCvrICh1tqwyhEAQYASABEgJGk_D_BwE

    @M/Jt 😁 I lost money in AUPH? I started to accumulate AUPH early 2017 when it was at @2.90. I posted on 2017-11-22: "I added 7,001 shares @4.28-4.68 on 11/15/2017; 2000 shrs @5.48 11/14/17; 2000 shrs @5.66 10/26/17; 2000 shrs @5.76 10/24/17; 2000 shrs @5.98 10/23/17; 2000 shrs @6.13 10/20/17; ... 4,000 shrs @5.90 around 8/8/17; & I added ..." * Unlike the shorts/bashers who are liars, I actually do what I say. I was accused of pumping AUPH when Yahoo Admin M shorted it at $3.52 on 10/10/2019. @frenkie C 😁 You need to say again "Araid owns only 99 $AUPH shares."😁

    This is how I invest in biotech: 4. LAST BUT NOT LEAST, enjoy my hobby/online-entertainment of taunting/striking back provocateurs; 3. Take it easy at bad times; 2. Have patience; 1. Pick up the right gold bag stocks. AUPH/SRNE's great science & pipeline will shine. Patience is the key to the ultimate success of the investors. Before Ariad was bought out, I had been accumulating its shares for 18.5 years with my belief that its great science & pipeline would shine. Time will let my haters know $SRNE / $AUPH are even big gold bags than $ARIA gold bags. Cheers!

    I don't set stop loss. I don't buy on margin. I don't sell but add more when it pulls back. What can the manipulators/shorts/paid-bashers do to my gold bags? Ah? AUPH/SRNE has very bright future. Patience is the key to the ultimate success of a true long's investment. I believe AUPH/SRNE will be my next ARIA. I buy and hold AUPH/SRNE the way I accumulated ARIA gold bags. I always pick up gold bags whenever the price is right to me. No bags, no gold! Traders definitely won't agree with me. Please mute me.
    ------------------
    @Yahoo Admin M/Jt/Fake Ariadlnvestor 🤣 You bought NIO @ $39? To madden you, I'd like to tell you I bought NIO/NK @ $1.99/$1.15 on 11/08/2019. I took my cost basis out by writing covered calls against only 1/3 of my NIO/NK shares 8 months later.😁 I lost money in SRNE? I took some profits @ $10/$18.82 on 2020-05-18/2020-08-10 "to take out cost basis & free roll it" in K Smooth's words.

    Sorrento's great science/pipeline is shining! 👍✔ Only the faithful true longs will be greatly rewarded. So I added 10,000 shares @$1.57/@$1.52 on 2019-11-18 knowing its great science/pipeline would shine. * ARIA dropped with the market to $0.78 on 2008-12-29. So what? I took the advantage! I added thousands of shares at $0.81/$0.80 although I had lost my job. I swear to God I still held the added shares when Ariad was bought out at $24 on 2017-01-09.
    Each decanter of LOUIS XIII Cognac is the life achievement of generations of cellar masters. Good Spirits. Delivered.
    Each decanter of LOUIS XIII Cognac is the life achievement of generations of cellar masters. Good Spirits. Delivered.
    www.reservebar.com
    Bullish
  • P
    Paul
    Good morning folks, let’s brake down why Sorrento’s yesterday evening announcement of positive results for a Phase 1B Trial of COVI-MSC (stem cell drug for rescue or tissue repair) is so important.

    Let’s first understand what is ARDS? ARDS (Acute Respiratory Distress Syndrome) happens when the lungs become severely inflamed from an INFECTION or INJURY. The inflammation causes fluid from nearby blood vessels to leak into the tiny air sacs in your lungs, making breathing increasingly difficult.

    The lungs can become inflamed after getting PNEUMONIA, SEVERE FLU, SMOKE INHALATION (FIRE), or COVID-19. AS YOU CAN SEE A HUGE POTENTIAL MARKET.

    There is currently NO CURE for ARDS. Survival rates for ARDS vary depending on age, the underlying cause of ARDS, associated illnesses, and other factors. Some studies estimate the MORTALITY RATE of ARDS to be between 36-52% per 100,000 people. So extremely high, and probably more so in COVID CASES.

    Now we know why the trial results for COVI-MSC while in Phase 1 are such good news. Ji, as per the recent Riley presentation, will after 40 patients apply for EUA if the initial data remains the same. My opinion personally is that if a person can be discharged from ICU after 8 days administration of stem cells that EUA will be given.

    MOST 1B Trials, which are for safety, involve 10-20 patients. GIVEN that JI mentioned 40 patients I’m thinking this is a PHASE 1B/2 TRIAL. While the trial estimated completion date is Jan 15,2022 I would not be to concerned for the impatient investor. Think along these lines. OWS to speed things along with government contracts in tow, and ending in a EUA way before the estimated primary completion date. Though trials can still be ongoing.

    This folks is why we should be extremely excited about the Phase 1 Trial results. This goes way beyond just a COVID application. Good luck, and as always do your dd.

    Oh one last thing, the WHITE HOUSE CORONAVIRUS TASK FORCE asked PSC to file for ACCELERATED FDA APPROVAL (they asked them) for PHASE 1 TRIAL for COVID-19. They immediately submitted the FDA request, and received FDA APPROVAL QUICKLY. So don’t expect speed bumps in our way folks :)
    Bullish
  • T
    Tom
    The robinhood brigade will be targeting any companies w a high short float % the rest of the week. Some of the AH gains for the companies on the Barron's list are incredible. Srne is going to be riding this wave the next 6 trading days. Positive PR is only going to drive the rally higher but even no news... People are cashing in on the shorts and If these investors hold until the big shorts are bankrupt (Melvin) before moving to another target, there is going to be a massive redistribution of wealth.
    I actually anticipate a change in the regulations to counter act this soon but hopefully not before srne longs taste a little redemption.
    If you agree, like the post and the shorts will take notice and leave us alone!
  • S
    Siphen
    The stock price move is based on a covid19 cure for critically ill patients, something no other company has been able to produce through this entire pandemic. The cherry on top is this cure wasn't even something investors were aware was happening now. It was slated for testing in August of 2021, was moved up to January. The analyst price targets were $35 without this cure. This is a game changer. Who wants to get back to normal life? SRNE can get us there.
  • S
    Sammy
    Breaking news: "Sorrento Announces Positive Preliminary Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients"

    https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-positive-preliminary-results-phase-1b-study
  • H
    HughJaynus
    The first three patients enrolled tolerated treatment well and improved rapidly. Each of the three patients was discharged from the hospital within a week of starting the patient’s COVI-MSC infusions and two patients were discharged on the day of their last infusion. One of the patients had been in the hospital for three weeks, unable to be weaned from significant oxygen support, and another patient with uncontrolled diabetes had been discharged previously but had to be readmitted due to recurrent ARD. Each of the infusions were well-tolerated and no patient reported any infusion-related adverse events. A fourth patient is currently at the beginning of a course of treatment, with no safety issues following the patient’s first infusion. Additional enrollment continues.
  • D
    DougWin
    Good morning to the Sorrento fan club, may you be prosperous by owning this amazing life saving company in 2021 and beyond!

    SRNE has the "CURE", as the preliminary data indicated in its early clinical trials that the Covi MSC saved patients from ICU, Covi AMG is also very potent even against virus mutants. Our Covi Stix and Track aim to detect early COVID symptoms, we have the COVID turn-key solutions: Detect early (highly sensitive and accurate test kits - Stix, Track), treat early (COVI AMG, Drops) and repair early (COVI MSG). IMHO, just the COVID pipeline itself , SRNE worth more than 10billion MC (SP=40), not to mention that our incredible pain & cancer drugs that are in phase 3 trials, and numerous subsidiaries that are about to go IPOs, our cash position is stronger than ever.

    I truly believe that a perfect storm (like the one at Gamestop) is brewing for SRNE, it's coming.... I can just smell the burning smoke of the SHORT ribs on the grill at my backyard. Shorts - go ahead to ruin your families, just like Citron got destroyed by GME!

    Chuck, Robert S, Paul Et al, please write a nice piece of thesis (post on Twitter, FB, Reddit) to tell the world that Sorrento has the cure and will save many lives once FDA approval, let's have our grass root moment to rebel against the short hedge funds, our GME moment could come any day now.

    Buckle up longs, enjoy the ride, cheers!
  • P
    Paul
    This is big news. This was mentioned in Riley presentation. Ji will apply for EUA after around 40 patients. Note 8 dates from initial IV being administered patients discharged from ICU. The turnaround time is quick.
  • J
    Jose V
    News Release
    Sorrento Announces Positive Preliminary Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients
    January 26, 2021 at 7:09 PM EST

    First three patients discharged from Hospital ICU within 8 days from initial IV administration
    No infusion-related adverse events noted for any patient treated to date
  • J
    Jesse Davis
    A break with tradition.

    Generally SRNE sells off after the good news is released, because it's already run up strong in advance. This time is different. It ran up in advance, and now is up again post-PR. Here's why I think that is the case...

    No one expected Covi-MSC to succeed. Not even on the first few patients. This is the equivalent of Tom Brady's halftime heave on Sunday versus the Packers. Nobody saw it coming, and while it didn't win the game, it kinda-sorta did end up winning it in the end!

    Ji has demonstrated a propensity for investing spectacularly in the past few months. This is 3 major hits in the last several months, adding up to 100s of millions of dollars in stock equity and potential revenue. Beyond Covi-MSC, we have been given a heads-up about Covid-2020 and the cancer therapeutic turned Covi-5959. So with about 18 irons in the fire, and at least a few nearing the boiling point, another scenario has come into play...

    GME and AMC are recent examples of a new breed taking advantage of tremendous market opportunity. I think little SRNE is actually on their radar. I don't think this is a paradigm shift of trading, but it is a window of opportunity that could put the wind in our sails. In fact, that may be happening this morning.

    Finally, there's the distinct possibility that we see a machine gun fire type of positive news cycle with SRNE. And the Covi-MSC may have just been the warning shot.

    God bless and happy hunting!
    Bullish
  • A
    Asaf
    Told you pre market this goes $15 today, see my post.
    At the same breath, I said it will go to $20 next. congratulations to all longs.
    Bullish
  • J
    Jesse Davis
    Congrats fellow SRNE longs! It was a battle, but we hung in there, and it was well worth the effort. Yesterday was Part One of the saga. Today is Part Two (several hours to go) and I feel like tomorrow will be Part Three of our story: "The Launch of SRNE"
    All we've seen is really the beginning of the ending of the shorts and accumulators control. It is now as the PR train arrives, that the value of SRNE begins to become realized in the share price and market cap!
    Dr. Henry Ji has done a masterful job of preparing SRNE for the modern situation of pandemic, fear and even market collapse. This is one of the few safer havens to weather the arriving storm.
    God bless!
    Bullish
  • j
    joseph
    News Release
    Sorrento Announces Positive Preliminary Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients
    January 26, 2021 at 7:09 PM EST
    Download PDF
    • First three patients discharged from Hospital ICU within 8 days from initial IV administration  
    • No infusion-related adverse events noted for any patient treated to date 
    SAN DIEGO, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today positive preliminary results from its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC™) for patients suffering from COVID-19-induced acute respiratory distress (ARD) or acute respiratory distress syndrome (ARDS). This ongoing study (PSC-CP-004) is a single arm, non-randomized Phase 1b study of the safety and preliminary efficacy of COVI-MSCs administered every other day for three infusions for a total of 1 x 106 cells/kg. The primary objective is to evaluate the safety of intravenous infusion of allogeneic adipose MSC cells in patients with COVID-19-induced ARD or ARDS. The secondary objective is to evaluate efficacy outcome variables to give guidance regarding the risk/benefit ratio in patients with COVID-19 respiratory distress.  
    The first three patients enrolled tolerated treatment well and improved rapidly. Each of the three patients was discharged from the hospital within a week of starting the patient’s COVI-MSC infusions and two patients were discharged on the day of their last infusion.  One of the patients had been in the hospital for three weeks, unable to be weaned from significant oxygen support, and another patient with uncontrolled diabetes had been discharged previously but had to be readmitted due to recurrent ARD. Each of the infusions were well-tolerated and no patient reported any infusion-related adverse events. A fourth patient is currently at the beginning of a course of treatment, with no safety issues following the patient’s first infusion. Additional enrollment continues. 
    Dr. Eyad Almasri, Associate Professor of Medicine, Pulmonary, Critical Care and Sleep Medicine at UCSF Fresno, is the principal investigator in this ongoing study.  Dr. Almasri stated, “I am excited to see how well-tolerated this promising treatment is to date and am very encouraged by the early signals we are seeing from the first few patients.  I am looking forward to working with Sorrento in continuing to offer COVI-MSC treatments to patients in this study and in the proposed controlled phase 2 study.” 
    More information on the Phase 1 trial can be found at www.clinicaltrials.gov (NCT04486001). Information on the proposed Phase 2 trial is expected to be available soon. 
    Stem cells have been demonstrated to support resolution of symptoms in multiple disease settings and have the potential to reduce the long-term effects associated with pulmonary tissue damage. More information on the potential use and benefits of MSCs for patients with COVID-19 can be found in the recently published review at: https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-020-02380-2
    Personalized Stem Cells, Inc. (PSC) is the GMP manufacturer partner for Sorrento’s COVI-MSC.
    In late 2019, a novel coronavirus (SARS-CoV-2) emerged in Wuhan, capital city of Hubei province in China. Cases of SARS-CoV-2 infection quickly grew by several thousand per day. Less than 100 days later, the World Health Organization declared that th
    In late 2019, a novel coronavirus (SARS-CoV-2) emerged in Wuhan, capital city of Hubei province in China. Cases of SARS-CoV-2 infection quickly grew by several thousand per day. Less than 100 days later, the World Health Organization declared that th
    translational-medicine.biomedcentral.com
  • D
    Don
    This news about the first 4 ARDS patients is very important. There is a potential EUA here! More patients needed but enrollment should be rapid! This is #7 on the list I posted earlier today. There's a lot of good news coming.

    8 potential Emergency Use Authentication candidates...all Blockbusters!
    1. Covi-Stix rapid accurate virus test
    2. Covi-Track rapid accurate antibody test
    3. Covi-push 2020 injection
    4. Covi-Drops 2020 nose drops
    5. Covi-Vax 2020 lipid DNA injection
    6. Abivirtinib ARDS prevention
    7. Stem Cell ARDS treatment
    8. Covi-Shield antibody cocktail
    Each of these EUA's could be accompanied by Operation Warp Speed grants and multi-billion dollar international sales. Additionally there could multi-billion dollar worldwide marketing partnerships.

    Timing? Some could come in days. Some in weeks. Others in several months.
  • H
    HighReturnStockTraders
    Who is selling SRNE stocks at $14.48 when it worth $35 soon.
    STRONG BUY!
    Bullish
  • D
    DougWin
    There is a real possibility that the Gamestop phenomenon will happen on SRNE! There are possible catalysts coming in the next couple of weeks

    1. COVI Stix approval
    2. Covi Track approval
    3. Covi AMG phase 2/3
    4. Abivertinib trial data and EUA
    5. Covi MSC phase 2 (in a month)
    6. BARDA funding of any of the above

    Get excited longs, having a vision of putting the shorts on the grill - the short ribs :) ...GLTA!
  • A
    Amrit
    Sorrento hopes to advance COVI-MSC to a controlled phase 2 study. In the meantime, the company is seeking Emergency Use Authorization for its COVI-STIX antibody test for COVID-19, and is evaluating several other potential coronavirus therapies in clinical studies.